News | August 14, 2014

First U.S. Commercial Neuraceq Scan for Beta-amyloid Plaque Imaging Performed at WVU Healthcare

First U.S. Commercial Neuraceq Scan Beta-amyloid Plaque Imaging  WVU Healthcare

August 14, 2014 ? Piramal Imaging announced that WVU Healthcare in West Virginia, is the first center in the United States to perform commercial scans using Neuraceq. Neuraceq became available for commercial use on Aug. 1, marking the first time patients are able to receive Neuraceq scans in the United States outside of research studies.

Neuraceq, which received marketing authorization in the European Union and in the United States earlier this year, is a radiopharmaceutical indicated for positron emission tomography (PET) imaging of the brain to estimate beta-amyloid neuritic plaque density in adult patients with cognitive impairment who are being evaluated for Alzheimer’s disease (AD) and other causes of cognitive decline. A negative beta-amyloid scan may help rule out AD as a cause of a patient’s cognitive decline. A positive Neuraceq scan indicates moderate to frequent amyloid neuritic plaques; neuropathological examination has shown this amount of amyloid neuritic plaque is present in patients with AD, but may also be present in patients with other types of neurologic conditions as well as older people with normal cognition. Prior to the availability of this technology a confirmation of the clinical diagnosis of AD could only be accomplished through autopsy.

The U.S. Food and Drug Administration (FDA) approved Neuraceq earlier this year.  Neuraceq scans will be available commercially for referring physicians and patients across the United States in the coming weeks and months.

”At WVU Healthcare, we are making history as the first center in the U.S. to offer patients access to beta-amyloid imaging with florbetaben without enrolling in a research trial,” said Gary D. Marano, medical director of nuclear medicine and PET/CT. “For us as clinicians, it’s a new diagnostic option to offer patients and referring physicians in cases of cognitive decline and concerns for Alzheimer’s disease.”

“As a company dedicated to innovation in molecular imaging, it was important to deliver Neuraceq into hands of trained dementia experts as soon as possible to start advancing treatment options and improving patient outcomes.” said Friedrich Gause, COO, Piramal Imaging. “We view this as an important milestone but just the beginning of our work to bring beta-amyloid imaging to the U.S. patient population.”

For more information: www.piramal.com/imaging

Related Content

MaxQ AI Launches Accipio Ax Slice-Level Intracranial Hemorrhage Detection
Technology | Computer-Aided Detection Software | May 21, 2019
Medical diagnostic artificial intelligence (AI) company MaxQ AI announced that Accipio Ax will begin shipping in August...
New Study Evaluates Head CT Examinations and Patient Complexity
News | Neuro Imaging | May 17, 2019
Computed tomography (CT) of the head uses special X-ray equipment to help assess head injuries, dizziness and other...
Brain images that have been pre-reviewed by the Viz.AI artificial intelligence software to identify a stroke. The software automatically sends and alert to the attending physician's smartphone with links to the imaging for a final human assessment to help speed the time to diagnosis and treatment. Depending on the type of stroke, quick action is needed to either activate the neuro-interventional lab or to administer tPA. Photo by Dave Fornell.

Brain images that have been pre-reviewed by the Viz.AI artificial intelligence software to identify a stroke. The software automatically sends and alert to the attending physician's smartphone with links to the imaging for a final human assessment to help speed the time to diagnosis and treatment. Depending on the type of stroke, quick action is needed to either activate the neuro-interventional lab or to administer tPA. Photo by Dave Fornell.

Feature | Artificial Intelligence | May 17, 2019 | Inga Shugalo
With its increasing role in medical imaging,...
New Phase 2B Trial Exploring Target-Specific Myocardial Ischemia Imaging Agent
News | Radiopharmaceuticals and Tracers | May 17, 2019
Biopharmaceutical company CellPoint plans to begin patient recruitment for its Phase 2b cardiovascular imaging study in...
Videos | Advanced Visualization | May 16, 2019
This is an example of how virtual reality is being used in neuro-radiology to better evaluate patients using advanced
Blue Earth Diagnostics Expands Access to Axumin in Europe
News | Radiopharmaceuticals and Tracers | May 13, 2019
Blue Earth Diagnostics announced expanded access to the Axumin (fluciclovine (18F)) imaging agent in Europe. The first...
Shine Medical Technologies Breaks Ground on U.S. Medical Isotope Production Facility

Image courtesy of Amen Clinics

News | Radiopharmaceuticals and Tracers | May 10, 2019 | Jeff Zagoudis, Associate Editor
Shine Medical Technologies Inc. broke ground on their first medical isotope production facility in Janesville, Wis. U.S...
360 degree view inside an Interventional radiology lab at Henry Ford Hospital used for neuro-interventions and stroke.
360 Photos | 360 View Photos | May 06, 2019
This is a 360 degree photo view inside the neuro-interventional radiology lab at ...
A 3-D printed tungsten X-ray system collimator. 3D printed, additive manufacturing for medical imaging.

A 3-D printed tungsten X-ray system collimator. The tungsten alloy powder is printed into the form desired and is laser fused so it can be machined and finished. Previously, making collimators from Tungsten was labor intensive because it required working with sheets of the metal to create the collimator matrix. 

Feature | Medical 3-D Printing | April 29, 2019 | By Steve Jeffery
In ...